Clinical trial
Phase 2 Study of Sacituzumab Tirumotecan (Sac-TMT) in Salivary Gland Cancers - Saint-Tropez (LACOG 1824) Trial
NCT07928193 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started March 2027. Interventional study, Phase 2, 64 participants (estimated). Lead sponsor Latin American Cooperative Oncology Group; Brazil. Primary measures: Objective Response Rate (ORR) in Cohort 1 (ACC); Objective Response Rate (ORR) in Cohort 2 (Non-ACC).
How it compares
90 similar trials: same condition (Salivary Gland Neoplasms) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of Sacituzumab Tirumotecan (Sac-TMT) in Salivary Gland Cancers - Saint-Tropez (LACOG 1824) Trial
- Lead sponsor
- Latin American Cooperative Oncology Group
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- March 31, 2027
- Completion date
- March 31, 2032
- Enrollment
- 64 (estimated)
- Sites
- 15
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: adenoid cystic carcinoma of the salivary gland, salivary gland cancers
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 15
- Countries
- Brazil
- Lead sponsor
- Latin American Cooperative Oncology Group
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Cohort 1: Adenoid Cystic Carcinoma (ACC) | Experimental | Sacituzumab Tirumotecan (Sac-TMT) |
Show registry wordingParticipants with advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC) of the salivary gland who have received no more than three prior non-curative systemic treatment regimens. Participants receive Sacituzumab Tirumotecan (Sac-TMT) monotherapy at 4 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle for up to 12 cycles, or until disease progression, unacceptable toxicity, or withdrawal of consent. | ||
| Cohort 2: Non-Adenoid Cystic Carcinoma (Non-ACC) | Experimental | Sacituzumab Tirumotecan (Sac-TMT) |
Show registry wordingrticipants with advanced, recurrent, or metastatic non-adenoid cystic carcinoma (non-ACC) of the salivary gland who have received no more than three prior non-curative systemic treatment regimens. Participants receive Sacituzumab Tirumotecan (Sac-TMT) monotherapy at 4 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle for up to 12 cycles, or until disease progression, unacceptable toxicity, or withdrawal of consent. | ||
Primary endpoints
Registered primary outcome measures; 2 primary.
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR) in Cohort 1 (ACC) | Up to 12 cycles (approximately 12 months). |
Show registry wordingProportion of participants with a best overall response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 in the Adenoid Cystic Carcinoma cohort. | |
| Objective Response Rate (ORR) in Cohort 2 (Non-ACC) | Up to 12 cycles (approximately 12 months). |
Show registry wordingProportion of participants with a best overall response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 in the Non-Adenoid Cystic Carcinoma cohort. | |
Lead sponsor's other trials
Latin American Cooperative Oncology Group, most recent start first.
+42 more trials See the organization page
Similar trials
Same condition (Salivary Gland Neoplasms) and phase, most recent start first.
+85 more trials See the condition page